TNIK: The Next Frontier Beyond GLP-1 in Obesity
Why TNIK inhibitors could solve the muscle loss problem that limits current obesity drugs
April 2026 | MolForge Research
$100B+
Global obesity drug market (2030F)
0 companies
Developing TNIK inhibitors for obesity
01
The GLP-1 Muscle Loss Problem
GLP-1 receptor agonists (semaglutide/Wegovy, tirzepatide/Mounjaro) have transformed obesity treatment. However, 20–40% of weight lost is lean muscle mass, not fat. This reduces metabolic rate and limits long-term efficacy.
| Drug | Weight Loss | Lean Mass Loss |
|---|---|---|
| Semaglutide (Wegovy) | ~16% | ~39% of total |
| Tirzepatide (Mounjaro) | ~21% | ~25–33% of total |
| TNIK KO mice | Resistant to obesity | Muscle preserved |
02
TNIK Biology
TNIK knockout mice — Science Advances, 2023, Copenhagen University
- Protected against diet-induced weight gain
- Ate more, were more active
- Enhanced insulin sensitivity
- Protected against fatty liver (NAFLD)
- Maintained muscle mass
- UK Biobank: TNIK variants associated with BMI, HbA1c, blood glucose
Mechanism
TNIK controls de novo lipogenesis. Inhibiting TNIK prevents dietary sugars from converting to fat, while preserving muscle function. Unlike GLP-1, it doesn't suppress appetite — it redirects energy metabolism.
03
Clinical Validation
- Insilico Medicine rentosertib — Phase 2a success (Nature Medicine, June 2025)
- Eli Lilly × Insilico $2.75B deal (March 2026)
- Indication: IPF (idiopathic pulmonary fibrosis), NOT obesity
“Insilico's success validates TNIK as a druggable target. The obesity opportunity remains completely untapped.”
04
Competitive Landscape
| Company | Target | Indication | Obesity? |
|---|---|---|---|
| Insilico | TNIK | IPF | NO |
| Carna Bio | TNIK | Colorectal cancer | NO |
| Novo Nordisk | GLP-1 | Obesity | YES (muscle loss) |
| MolForge | TNIK | CRC + Obesity | YES (no muscle loss) |
05
MolForge Position
33,755
TNIK compounds ADMET-validated
3×
Verification: QSAR + Vina + GNN
4
Leads in CRO validation
<0.21
Tanimoto vs rentosertib (FTO safe)
Dual indication strategy: colorectal cancer (lead) + obesity (expansion). Both indications share the same TNIK target, enabling shared compound libraries and parallel development.
06
Market Opportunity
| Market | Size (2030F) |
|---|---|
| Obesity | $100B+ |
| Type 2 Diabetes | $80B+ |
| NAFLD | $30B+ |
| Colorectal Cancer | $15B+ |
Interested in TNIK inhibitor licensing?
MolForge is seeking licensing partners for TNIK inhibitor programs in obesity and colorectal cancer.
Contact UsReferences
- [1]Pham, D.D. et al. "TNIK knockout prevents diet-induced obesity by enhancing energy expenditure." Science Advances, 2023.
- [2]Masuda, M. et al. "TNIK inhibition abrogates colorectal cancer stemness." Nature Communications, 2016.
- [3]Pun, F.W. et al. "AI-powered therapeutic target discovery." Trends in Pharmacological Sciences, 2024.
- [4]Ren, F. et al. "Rentosertib — an AI-discovered TNIK inhibitor for IPF." Aging and Disease, 2026.
- [5]Levin, J. et al. "Rentosertib Phase 2a results in idiopathic pulmonary fibrosis." Nature Medicine, 2025.
- [6]Eli Lilly and Insilico Medicine announce $2.75B licensing agreement. Press release, March 2026.
- [7]Novo Nordisk partners with OpenAI for AI-driven drug discovery. Press release, 2026.